Morgan Stanley and Citigroup raised price objectives on Amgen shares, with MarketBeat reporting the consensus rating.
1 report, 1 independent
Updated Wed 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley and Citigroup raised price objectives on Amgen shares, with MarketBeat reporting the consensus rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Morgan Stanley
U.S. investment bank
-
Citigroup
American investment bank and financial services corporation
- Citigroup, Benchmark, Scotiabank, and Jefferies Financial Group provided financial ratings and analysis on November 1, 2026.
- Citigroup reiterated a market perform rating, Bank of America restated an underperform rating, and Raymond James Financial started coverage for Omega Healthcare Investors, Inc.
Related events
- Citigroup reduced its price objective for Morgan Stanley stock on October 18, 2026.
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- Citigroup increased its price objective on Oceaneering International stock, while MarketBeat reported the consensus rating.
- Citigroup reduced its price objective for ProKidney, with stock changes and ratings reported by Benzinga and MarketBeat.
- Citigroup lifted its price objective on Newmont Corporation stock.